2018-12-10T15:43:05-06:00 2017-12-31 042088368 GRAY GRAY & GRAY LLP 150 ROYALL STREET SUITE 102 CANTON MA 02021 990 2017-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST NO 200 WELLESLEY HILLS MA 02481 TIMOTHY W ARMOUR PRESIDENT 7812373800 2018-12-10 1 MICHAEL L CECERE P00236848 7814070300 2018-12-10 50.234.152.46 2018-12-10 12:42:07 ES 04350320181210338e03 2018-05-01 P 10A63E3C5C97A0BFB18ADDEB83B66A1433F48046 5766E4DEBA5607345FCC8B9F4780E23D8E395EC6 2017 2019-02-21 02:37:17Z X CURE ALZHEIMER'S FUND TIMOTHY W ARMOUR 34 WASHINGTON STREET WELLESLEY HILLS MA 02493 21616990 0 X WWW.CUREALZ.ORG X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTRHOPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 7 6 22 68 0 0 16220862 17501551 0 0 -63796 -7084 90 3644 16157156 17498111 12429812 13884649 0 0 1298940 1321557 0 0 537838 2786682 3793348 16515434 18999554 -358278 -1501443 12463210 10939018 563695 530632 11899515 10408386 X FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE THROUGH VENTURE BASED PHILANTHROPY WITH ALL ORGANIZATIONAL EXPENSES PAID BY THE BOARD, ALLOWING ALL PUBLIC CONTRIBUTIONS TO DIRECTLY FUND ALZHEIMER'S RESEARCH. 0 0 15705484 13884649 IN 2017, CURE ALZHEIMER'S FUND SUPPORTED 68 RESEARCH PROJECTS AT 38 LEADING RESEARCH INSTITUTIONS, FOR A FUNDING TOTAL OF MORE THAN $15 MILLION. THE MAJORITY OF PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT. ADDITIONAL EXPENSES INCLUDE THE DIRECT SUPPORT OF FACILITATING GRANTS AND THEIR AWARD PROCESS. 1946644 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 58172 CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVES FUNDS FROM THE METROPOLITAN LIFE FOUNDATION, DISPENSES THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTS THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION. CURE ALZHEIMER'S FUND SERVES AS FIDUCIARY AGENT FOR A SERIES OF INDEPENDENTLY PRODUCED VIDEOS ABOUT ALZHEIMER'S DISEASE. WITH AN EXECUTIVE PRODUCER, THE ORGANIZATION RECEIVES FUNDS FROM THE METROPOLITAN LIFE FOUNDATION, DISPENSES THEM AS APPROVED BY THE EXECUTIVE PRODUCER AND REPORTS THE FINANCIAL ACTIVITY PERIODICALLY TO THE METROPOLITAN LIFE FOUNDATION 17710300 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 31 0 1 22 1 0 0 0 0 0 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X TIMOTHY W ARMOUR 7812373800 34 WASHINGTON STREET STE 200 WELLESLEY HILLS MA 02481 JEFFREY MORBY CO-CHAIRMAN OF BOARD 20.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 5.00 X 0 0 0 HENRY MCCANCE CO-CHAIRMAN OF BOARD 5.00 X 0 0 0 PHYLLIS RAPPAPORT TREASURER 2.00 X X 0 0 0 ROBERT GREENHILL DIRECTOR 2.00 X 0 0 0 TIMOTHY W ARMOUR PRESIDENT & CEO 40.00 X X 238131 0 7144 SHERRY SHARP DIRECTOR 2.00 X 0 0 0 MARGARET SMITH SECRETARY & SR VICE PRESID 20.00 X 116030 0 3481 JOHN SLATTERY SENIOR VICE PRESIDENT 40.00 X 166052 0 4982 BARBARA CHAMBERS SVP, MARKETING & COMMUNICATIONS 40.00 X 158854 0 13671 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 40.00 X 162745 0 13924 841812 0 43202 5 0 1 0 PROPER VILLIANS LLC 668 STONY HILL RD YARDLEY MA 19067 CREATIVE SERVICES 236520 DAVID SHENK 216 ST JOHNS PLACE APT D BROOKLYN NY 11217 PROGRAM AND FUNDRAISING CONSULTING 164875 GRYPHON CONSULTING LLC 21 DEAN ST BELMONT MA 02478 FINANACIAL AND MANAGEMENT CONSULTING 149286 3 17501551 4108217 17501551 13021 13021 4098774 4118879 -20105 -20105 -20105 OTHER INCOME 900099 3644 3644 3644 17498111 -16461 0 13021 12852704 12852704 1031945 1031945 859760 570392 109665 179703 317981 92552 204377 21052 33029 21062 4585 7382 30357 7044 23313 80430 49021 14881 16528 6530 6530 132566 132566 330372 221720 53214 55438 93357 87098 6259 25899 25307 592 123215 69000 33268 20947 141661 65878 31580 44203 8107 8107 18342 18342 4752 4752 RESEARCH EXPENSES 1820835 1820835 PUBLIC RELATIONS 132050 132050 GOVERNMENT RELATIONS 110065 110065 MARKETING MATERIALS 103882 103882 741715 466945 89036 185734 18999554 17710300 751416 537838 2792710 4096006 6371310 179386 3097825 2437328 141354 183265 60997 18140 50909 42857 3990040 9102 10136 12463210 10939018 260603 319678 303092 210954 563695 530632 X 8710240 8303832 3189275 2104554 11899515 10408386 12463210 10939018 -1501443 10314 0 X 0 1 X 1 0 X 6388347 12640759 11248214 16220862 17501551 63999733 6388347 12640759 11248214 16220862 17501551 63999733 10376032 53623701 -15933 11420 -3438 -63796 -7084 -78831 10000 3150 90 3644 16884 63937786 0.83870 0.80730 X 0 0 0 0 0 0 1 110065 0 0 110065 0 PART II-B, LINE 1: PART II-B, LINE 1(I), OTHER LOBBYING ACTIVITIES: A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 9939 5027 4912 51058 13113 37945 42857 ACCRUED EXPENSES 210954 210954 X 17512187 10314 3762 14076 17498111 0 17498111 19003316 3762 3762 18999554 0 18999554 PART X, LINE 2: CUREALZ WAS DETERMINED TO BE EXEMPT FROM FEDERAL INCOME TAX UNDER PROVISIONS OF SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE OF 1986 (IRC) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION AS DEFINED IN SECTION 509(A)(3) OF THE IRC. ACCORDINGLY, NO PROVISIONS FOR FEDERAL OR STATE INCOME TAXES ARE REQUIRED. CUREALZ IS REQUIRED TO RECOGNIZE THE FINANCIAL STATEMENT IMPACT OF A TAX POSITION WHEN IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION. ANY INTEREST AND PENALTIES RECOGNIZED ASSOCIATED WITH A TAX POSITION WOULD BE CLASSIFIED AS CURRENT IN CUREALZ'S FINANCIAL STATEMENTS. CURRENTLY, THE TAX YEARS ENDED DECEMBER 31, 2014, 2015, AND 2016 ARE OPEN AND SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE AND THE MASSACHUSETTS DEPARTMENT OF REVENUE. HOWEVER, CUREALZ IS NOT CURRENTLY UNDER AUDIT NOR HAS CUREALZ BEEN CONTACTED BY ANY OF THESE JURISDICTIONS. BASED ON THE EVALUATION OF CUREALZ'S TAX POSITIONS, MANAGEMENT BELIEVES ALL POSITIONS TAKEN WOULD BE UPHELD UNDER AN EXAMINATION. THEREFORE, NO PROVISION FOR THE EFFECTS OF UNCERTAIN TAX POSITIONS HAS BEEN RECORDED FOR THE YEAR ENDED DECEMBER 31, 2017. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM GRANTS AWARDED 633487 NORTH AMERICA GRANTS AWARDED 248458 EAST ASIA AND THE PACIFIC 150000 0 0 0 0 0 0 1031945 0 1031945 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPUTIC MODULATION OF TREM2 ACTIVITY. 112000 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM GENE EXPRESSION THROUGHOUT DEVELOPMENT OF PATHOLOGY IN APPKI MICE; EFFECTS OF HUMAN TAU AND AGEING 198987 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM MANDELKOW ADD-ON: TAU MISSORTING IN ALZHEIMER'S DISEASE - CAUSES AND CONSEQUENCES 172500 CHECK EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DEWILDE/DE STROOPER NANOBODIES TO CROSS THE BLOOD-BRAIN BARRIER 150000 CHECK NORTH AMERICA USING HUMAN BIOENGINEERED CEREBRAL VESSELS TO EXPLORE HOW NATIVE APOLIPOPROTEIN E AFFECTS CEREBROVASCULAR PROPERTIES RELEVANT TO AD 248458 CHECK EAST ASIA AND THE PACIFIC 150000 CHECK 0 0 0 0 0 0 PART I, LINE 2: THE CHAIR OF THE RESEARCH CONSORTIUM (RC) AND SUITABLE MEMBERS OF THE RC AND SCIENTIFIC ADVISORY BOARD (SAB) REVIEW EACH PROPOSAL FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S. THE BOARD OF DIRECTORS OF CURE ALZHEIMER'S FUND PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY MEMBER OF THE RC, SAB OR EXECUTIVE COMMITTEE WILL BE RETURNED TO THE RESEARCHER FOR CLARIFICATION. SUCH QUESTIONS OR CONCERNS MAY RESULT IN MODIFICATION AND RESUBMISSION, OR, IN EXTREME CASES, REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTION, OR REJECTION. THERE IS NO "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION WHEN RESEARCHERS ARE NOTIFIED THAT A PROPOSAL WILL BE FUNDED. 1 CARNEGIE MELLON UNIVERSITY 4400 FIFTH AVE PITTSBURGH PA 15213 501(C)(3) 193786 CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 501(C)(3) 150000 EARLY ROLE OF MICROGLIA IN SYNAPSE LOSS IN ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 501(C)(3) 200000 INVESTIGATING THE MECHANISM OF ENTORHINAL CORTEX HYPERMETABOLISM IN APOE4 TARGETED REPLACEMENT MICE DUKE UNIVERSITY SCHOOL OF MEDICINE 8 DUKE UNIVERSITY MEDICAL CENTER GREENSPACE DURHAM NC 27703 501(C)(3) 152276 PATHWAY CROSS-TALKS ASSOCIATED WITH SEX AND RISK FOR ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 501(C)(3) 250000 THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 501(C)(3) 150000 GOLD ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 501(C)(3) 250000 LAN ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAE L LEVY PLACE NEW YORK NY 10029 501(C)(3) 150000 VGF, A NOVEL THERAPEUTIC EFFECTOR OF ALZHEIMER'S DESEASE PATHOGENESIS AND PROGRESSION JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK NY 10065 501(C)(3) 150000 REGULATION OF MICROGLIAL LYSOSOME ACIDIFICATION MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 350000 CHRONIC VIRAL NEUROINFECTION MEDIATES B-AMYLOID DEPOSITION IN TRANSGENIC AD MICE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 250000 COMPOUNDS MODULATING MICROGLIAL UPTAKE OF AMYLOID BETA AND CD33-TARGETED IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 250000 HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN NEURAL CULTURE SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 021394307 501(C)(3) 100000 EVALUATION OF BLOOD-BRAIN BARRIER (BBB) PENETRATION OF ALZHEIMER'S DRUG TARGETS AND IDENTIFICATION OF BBB INTEGRITY ENHANCERS COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 501(C)(3) 320106 PROPAGATION OF TAUOPATHY AND UPS DYSFUNCTION IMPACT AND RESCUE WITH A UPS ACTIVATOR COLUMBIA UNIVERSITY 710 WEST 168TH STREET 3RD FLOOR NEW YORK NY 10032 501(C)(3) 150000 NOVEL CHEMICAL MODULATORS FOR BACE 1-MEDIATED CLEAVAGE OF B-AMYLOID PRECURSON PROTEIN METHODIST HOSPITAL PO BOX 4384 HOUSTON TX 772104384 501(C)(3) 150000 UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DURG REPOSITIONING MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 250000 GUT MICROBIOME MEDIATED SHIFTS IN B-AMYLOID DEPOSITION IN A HUMANIZED AD MOUSE MODEL MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 200000 EXPLORING SEX DIFFERENCES IN AD PATHOGENESIS USING 3D HUMAN NON-CELL-AUTONOMOUS MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 100000 EVALUATION OF BLOOD-BRAIN BARRIER (BBB) PENETRATION OF ALZHEIMER'S DRUG TARGETS, AND IDENTIFICATION OF BBB INTEGRITY ENHANCERS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 150000 SWIRSHI NAHRENDORF SYSTEMIC INFLAMMATORY NETWORKS IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 125 NASHUA4500 SAN PABLO ROD S STREET JACKSONVILLE FL 32224 501(C)(3) 250000 APOE: BU YEAR MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 1500000 ALZHEIMER'S GENOME PROJECT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 200000 GENES TO THERAPIES (G@T) CENTRALIZED RESEARCH CORE MAYO CLINIC JACKSONVILLE PO BOX 414876 BOSTON MA 02114 501(C)(3) 200000 ABCA7 IN BRAIN HOMEOSTASIS AND ALZHEIMER'S DISEASE MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 501(C)(3) 150000 BIOCHEMICAL MAPPING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULATORS REGENTS OF THE UNIVERSITY OF CALIFORNIA 9500 GILMAN DRIVE SAN DIEGO CA 92093 501(C)(3) 150000 1TREATING WITH GAMMA-SECRETEASE MODULATORS TO PREVENT NEURODEGENERATION IN A MOUSE MODELS OF DOWN SYNDROME REGENTS OF THE UNIVERSITY OF CALIFORNIA 1400 BIOLOGICAL SCIENCES IRVINE CA 92697 501(C)(3) 150000 VALIDATION OF ENDOGENOUS HUMAN ANTIBODIES THAT ARE CORRELATED WITH AVOIDING ALZHEIMER'S DISEASE AND THEIR CORRESPONDING ANTIGENS, FOR IMMUNOTHERAPEUTIC DEVELOPMENT SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES ROAD LA JOLLA CA 92037 501(C)(3) 150000 MICROGLIAL TAM RECEPTORS AS MODULATORS OF ALZHEIMER'S PATHOLOGY SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 10901 N TORREY PINES ROAD LA JOLLA CA 92037 501(C)(3) 150000 SORA ATTENUATES A TOXICITY THROUGH INTERACTIONS WITH EPHA4 MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA STREET BOSTON MA 02114 501(C)(3) 287500 ROLE OF ATXN1 IN REGULATING BACE1 ACTIVITY NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 501(C)(3) 250000 MOLECULAR AND CELLULAR MECHANISMS OF AN ACE1 VARIANT IN ALZHEIMER'S DISEASE THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 250000 IMPACT OF APOE AND SEX ON VULNERABLE NEURON-SPECIFIC FUNCTIONAL NETWORK THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 450000 DISCOVERY OF CK1 ACTIVATORS FOR INDUCING THE AUTOPHAGIC DEGRADATION OF APP BETA-CTF THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 022151301 501(C)(3) 100000 INHIBITION OF TAU PATHOLOGY IN HUMAN NEURONS THE TRUSTEES OF BOSTON UNIVERSITY 25 BUICK STREET BOSTON MA 022151301 501(C)(3) 100000 ALZHEIMER'S DISEASE STEM CELL DRUG SCREENING IN 3D THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 250000 PROTEIN KINASE C IN ALZHEIMER'S DISEASE THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 150000 BIOCHEMICAL MAPPING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULATORS THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 501(C)(3) 125000 A COMBINATION OF ANTI-AB AND GROWTH FACTOR THERAPY FOR ALZHEIMER'S DISEASE UNIVERSITY OF CHICAGO 947 E 58TH STREET CHICAGO IL 60637 501(C)(3) 250000 IN VITRO AND IN VIVO ANALYSIS OF APP VARIANTS UNIVERSITY OF CHICAGO 947 E 58TH STREET CHICAGO IL 60637 501(C)(3) 175000 MECHANISMS BY WHICH THE GUT MICROBIOME INFLUENCES AMYLOID DEPOSITION AND NEUROINFLAMMATION IN MOUSE MODELS OF ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 501(C)(3) 250000 MOLECULAR AND CELLULAR MECHANISMS OF AN ACE1 VARIANT IN ALZHEIMER'S DISEASE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 9201 UNIVERSITY CITY BLVD CHARLOTTE NC 282230001 501(C)(3) 150000 A MICROFLUIDICS-BASED HUMAN BRAIN CELL 3D CULTURE SYSTEM IN ALZHEIMER'S DISEASE UNIVERSITY OF ROCHESTER 601 ELMWOOD AVENUE ROCHESTER NY 14642 501(C)(3) 150000 WILL RESTORATION OF NORMAL GLYMPHATIC FUNCTION SLOW PROGRESSION OF COGNITIVE DECLINE AND AMYLOID PLAQUES IN A MURINE ALZHEIMER MODEL? UNIVERSITY OF SOUTHERN CALIFORNIA 3720 FLOWER STREET LOS ANGELES CA 900892821 501(C)(3) 200000 THE ROLE OF PICALM MUTATIONS IN ALZHEIMER'S DISEASE UNIVERSITY OF SOUTHERN CALIFORNIA 3720 FLOWER STREET LOS ANGELES CA 900892821 501(C)(3) 156005 INTERACTIONS AMONG TREM2, APOE AND SEX UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 501(C)(3) 150000 THE ROLE OF MENINGEAL LYMPHATICS IN CLEANSING THE BRAIN: IMPLICATIONS FOR ALZHEIMER'S DISEASE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 501(C)(3) 190681 BLOOM LAZO SHARLOW: TARGETING CELL CYCLE RE-ENTRY USING 3D NEURON CULTURES WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 150000 MODELING NEURONAL AGING IN SPECIFIC SUBTYPES OF HUMAN NEURONS BY MICRORNA-MEDIATED NEURONAL REPROGRAMMING WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 300000 UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 115(1) 300000 TREM2: ROLE IN MODULATING AB AND TAU-RELATED PATHOLOGIES AND NEURODEGENERATION WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 02142 501(C)(3) 150000 MODELING DNA METHYLATION CHANGES IN ALZHEIMER'S DISEASE USING HUMAN-INDUCED PLURIPOTENT STEM CELLS TRUSTEES OF TUFTS COLLEGE 419 BOSTON AVE MEDFORD MA 02155 501(C)(3) 150000 FUNCTIONAL CHARACTERIZATION OF GGA3 MUTATIONS ASSOCIATED WITH ALZHEIMER'S DISEASE YALE UNIVERSITY 333 CEDAR ST NEW HAVEN CT 06510 501(C)(3) 150000 IMPACT OF INFLAMMASOME DEACTIVATION ON ALZHEIMER'S DISEASE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 9201 UNIVERSITY CITY BLVD CHARLOTTE NC 282230001 501(C)(3) 2350 3D HUMAN NEURAL CELL CULTURE SYSTEM - BRIDGE FUNDING UNIVERSITY OF RHODE ISLAND 45 UPPER COLLEGE ROAD KINGSTON RI 02881 501(C)(3) 150000 CEREBROVASCULAR DYSFUNCTION IN AD: TARGETING THE MECHANISMS OF VASCULAR ACTIVIATION UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 150000 GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 501(C)(3) 250000 APOE PROTEOFORMS IN HUMAN CNS AND VALIDATION OF APOE PHARMACODYNAMIC TRANSLATIONAL MARKERS WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 501(C)(3) 150000 TARGETING REACTIVE ASTROCYTES FOR THERAPEUTIC INTERVENTION ON ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 501(C)(3) 150000 STABLE ISOTOPE LABELING & QUANTITATIVE MASS SPECTOMETRY IMAGING OF ALZHEIMER'S DISEASE PATHOLOGY IN HUMAN WASHINGTON UNIVERSITY ST LOUIS 700 ROSEDALE AVE ST LOUIS MO 631121408 501(C)(3) 50000 AB KINETICS AND ENHANCING THE DIAGNOSTIC AND PROGNOSTIC CSF BIOMARKERS OF AD THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 150000 STIMULATING PROTEASOME ACTIVITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 501(C)(3) 150000 THE ROLE OF THE CONTACT SYSTEM IN ALZHEIMER'S DISEASE PART I, LINE 2: THE CHAIR OF THE RESEARCH CONSORTIUM (RC) AND SUITABLE MEMBERS OF THE RC AND SCIENTIFIC ADVISORY BOARD (SAB) REVIEW EACH PROPOSAL FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S. THE BOARD OF DIRECTORS OF CURE ALZHEIMER'S FUND PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROPOSAL FITS WITHIN THE ORGANIZATION'S MISSION TO FUND RESEARCH CONTRIBUTING TO A CURE FOR ALZHEIMER'S DISEASE. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY MEMBER OF THE RC, SAB OR EXECUTIVE COMMITTEE WILL BE RETURNED TO THE RESEARCHER FOR CLARIFICATION. SUCH QUESTIONS OR CONCERNS MAY RESULT IN MODIFICATION AND RESUBMISSION, OR, IN EXTREME CASES, REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTION, OR REJECTION. THERE IS NO "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION WHEN RESEARCHERS ARE NOTIFIED THAT A PROPOSAL WILL BE FUNDED. X X 0 0 0 0 0 0 0 0 0 TIMOTHY W ARMOUR PRESIDENT & CEO 238131 0 0 0 0 0 7144 0 0 0 245275 0 0 0 JOHN SLATTERY SENIOR VICE PRESIDENT 166052 0 0 0 0 0 4982 0 0 0 171034 0 0 0 BARBARA CHAMBERS SVP, MARKETING & COMMUNICATIONS 158854 0 0 0 0 0 4766 0 8905 0 172525 0 0 0 SALLY G ROSENFIELD SENIOR VICE PRESIDENT 162745 0 0 0 0 0 4882 0 9042 0 176669 0 0 0 PART I, LINE 3 A COMPENSATION COMMITTEE REVIEWS ALL COMPENSATION ANNUALLY. X 78 4108217 CLOSE OF BUSINESS 0 0 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR AS SOON THEREAFTER AS IS PRACTICAL THROUGH BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 2 JEFFREY MORBY AND JACQUELINE MORBY ARE BOTH DIRECTORS AND SPOUSES. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT REVIEWS THE FORM 990 AND PROVIDES COPIES TO THE DIRECTORS BEFORE APPROVING THE FORM FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE PRESIDENT REGULARLY AND CONSISTENTLY MONITORS COMPLIANCE WITH CONFLICTS OF INTEREST BY REQUESTING THAT ALL OFFICERS, DIRECTORS, AND FOUNDERS RADIFY AN ANNUAL STATEMENT DISCLOSING ALL INTERESTS THAT MIGHT CONFLICT WITH ANY INTEREST OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE PRESIDENT AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE. PAGE 1, BOX B - AMENDED RETURN THE FOLLOWING PARTS AND LINES WERE AMENDED TO REFLECT THE CORRECT NUMBER OF VOTING AND INDEPENDENT MEMBERS OF THE GOVERNING BOARD: PART I, LINE 1 CHANGED FROM 9 ON THE ORIGINAL RETURN TO 7 ON THE AMENDED RETURN. PART I, LINE 2 CHANGED FROM 7 ON THE ORIGINAL RETURN TO 6 ON THE AMENDED RETURN. PART VI, SECTION A, LINE 1A CHANGED FROM 9 ON THE ORIGINAL RETURN TO 7 ON THE AMENDED RETURN. PART VI, SECTION A, LINE 1B CHANGED FROM 7 ON THE ORIGINA RERTURN TO 6 ON THE AMENDED RETURN. PART VII, SECTION A, LINES 1A (9) AND (10) CHANGED FROM OFFICER ON THE ORIGINAL RETURN TO KEY EMPLOYEE ON THE AMENDED RETURN. PART VII, SECTION A, LINE (11) CHANGED FROM TITLE OF SENIOR ENGMT OFFICER, MARKETING TO SVP, MARKETING & COMMUNICATIONS.